A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

NCT04501523 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

460

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: Tislelizumab
DRUG: capecitabine

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University